Bruno Fautrel1, Gabrielle Cukierman2, Jean-Michel Joubert2, Caroline Laurendeau3, Julie Gourmelen4, Francis Fagnani3. 1. UPMC-GRC 08, institut Pierre-Louis d'épidémiologie et Santé publique, 75252 Paris cedex 05, France; Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, AP-HP, 83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: bruno.fautrel@psl.aphp.fr. 2. UCB Pharma, 92700 Colombes, France. 3. Cemka-Eval, 92340 Bourg-la-Reine, France. 4. Inserm U1018 - UVSQ, 94807 Villejuif, France.
Abstract
OBJECTIVE: To estimate healthcare service utilisation costs of patients with rheumatoid arthritis in France and to estimate the fraction of these costs attributable to RA. METHOD: The "Échantillon généraliste des bénéficiaires" (EGB) is a 1/97 random sample of the main national claims database covering the French population. A cohort of patients with rheumatoid arthritis was constituted of all adults benefiting from full coverage for rheumatoid arthritis (ICD-10 M05-06) on 1st january 2009. A control group matched for age and gender was identified. Health expenditures were assessed from the payer's perspective for the year 2010. RESULTS: The annual per capita reimbursed total health expenditure was €6,404 in 2010, an amount around two times higher than in the control group €3,095 (P<0.0001). The main contributors to this extra cost were outpatient care (+€2,407; 72.7%), including medication (+€1,686; 50.0%), and inpatient care (+€903; 27.3%). Patients treated by biological agents generated an age-adjusted per capita annual expenditure about three times higher than untreated patients (€15,757 versus €4,640). CONCLUSION: Only half of medical expenditure by patients with rheumatoid arthritis is attributable to their disease and use of biological agents has become a major driver of cost.
OBJECTIVE: To estimate healthcare service utilisation costs of patients with rheumatoid arthritis in France and to estimate the fraction of these costs attributable to RA. METHOD: The "Échantillon généraliste des bénéficiaires" (EGB) is a 1/97 random sample of the main national claims database covering the French population. A cohort of patients with rheumatoid arthritis was constituted of all adults benefiting from full coverage for rheumatoid arthritis (ICD-10 M05-06) on 1st january 2009. A control group matched for age and gender was identified. Health expenditures were assessed from the payer's perspective for the year 2010. RESULTS: The annual per capita reimbursed total health expenditure was €6,404 in 2010, an amount around two times higher than in the control group €3,095 (P<0.0001). The main contributors to this extra cost were outpatient care (+€2,407; 72.7%), including medication (+€1,686; 50.0%), and inpatient care (+€903; 27.3%). Patients treated by biological agents generated an age-adjusted per capita annual expenditure about three times higher than untreated patients (€15,757 versus €4,640). CONCLUSION: Only half of medical expenditure by patients with rheumatoid arthritis is attributable to their disease and use of biological agents has become a major driver of cost.
Authors: A Burgun; E Bernal-Delgado; W Kuchinke; T van Staa; J Cunningham; E Lettieri; C Mazzali; D Oksen; F Estupiñan; A Barone; G Chène Journal: Yearb Med Inform Date: 2017-09-11
Authors: Mark Tatangelo; George Tomlinson; J Michael Paterson; Edward Keystone; Nick Bansback; Claire Bombardier Journal: PLoS One Date: 2021-05-06 Impact factor: 3.240